Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials

Overview

At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.

News

News Merck.com 5 years ago
Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study...
At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Merck Plans to Seek Emergency Use Authorization in the U.S. a
Read more
Report
News Merck.com 5 years ago
Merck Statement on Ivermectin use During the COVID-19 Pandemic
KENILWORTH, N.J., Feb. 4, 2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic. Company scientists continue to carefully examine the findings of a
Read more
Report
News MSD Privacy 6 years ago
Global Online Tracking Policy
At Merck & Co., Inc., Rahway, NJ, USA, known as
Read more
Report
News MSD Privacy 6 years ago
TRANSPARENCY AND PRIVACY
A key element in our approach to privacy at our company is our commitment to transparency in our privacy program. We aim to achieve this by providing clear and understandable notices of our privacy practices that enable our stakeholders to make meaningful
Read more
Report

Tech stack

Technologies named in job postings at Merck.com over the last 12 months, by layer, with the share of postings for each.
Technologies in use
7
Postings analysed
3
Stack modernity
81/100AI adopter
Languages
Python
SQL
Cloud & platforms
GCP
Databricks
AI & ML
LLM
Practices & domains
Good Clinical Practice
Machine Learning
Sign in to see how your skills match this stack Sign In

Salary insights

Compensation ranges based on this company's open jobs
Median
$224k
Typical range
$184k – $300k
Open positions
3
3 Jobs
Junior 33.3%
Senior 33.3%
Architect 33.3%
Level Jobs Median Typical range
Junior 1 $224k $224k
Senior 1 $184k $184k
Architect 1 $300k $300k
Highest paying role Regional Medical Scientific Director (aka Medical Science Liaison) Immunology $300k
Normalized to USD per year

People

David Johnson
Executive Officer, Director
Richard Vincent
Executive Officer
Langdon Miller
Executive Officer
Scott Karchmer
Executive Officer
Clayton Knox
Executive Officer
Michael Ross
Executive Officer
David Guyer
Executive Officer
Cam Gallagher
Director
Scott Glenn
Director
Min Cui
Director
Jayson Punwani
Director
Mark Chin
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Growth

Hiring Momentum
79/100
Scaling fast
Open positions
3
2 opened / 0 closed in 30 days
Median time-to-fill
26 days
faster than 48% of the market
Hiring Dynamics +100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Backend
20% ▲
Security
20% ▼
Leadership
20% ▲
Management
20% ▲
Science & Research
20% ▲
Activity Timeline
Added Microsoft Office to stack Oct 2026
Added HIPAA to stack Oct 2026

Offices

Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters Builds here Office with open vacancies No open vacancies right now Tap a pin for the office
San Diego United States
HQ
Media United States
Regional office
Media
company site

Jobs

$117k – $184k per year • Hybrid • Full-Time • Rahway
Python
Git
Analytics
ETL/ELT
Life Sciences
Chromatography
LIMS
Apply
$191k – $300k per year • Remote (United States, Puerto Rico) • Full-Time
GCP
Cybersecurity
HIPAA
Life Sciences
Good Clinical Practice
Apply

Financials

Total raised
$210.5M
Latest round
Venture - Series Unknown
Funding rounds
5
Funding rounds
Round Announced Amount
Venture - Series Unknown 2021 $486 Details
Venture - Series Unknown 2020 $137M Details
Venture - Series Unknown 2018 $59.3M Details
Venture - Series Unknown 2018 $6.5M Details
Venture - Series Unknown 2018 $7.7M Details